Cepheid
904 Caribbean Drive
Sunnyvale,
CA 94089-1189
United States - Map
Phone: 408-541-4191
Fax: 408-541-4192
Web Site: http://www.cepheid.com
| Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for genetic testing in the clinical molecular diagnostic, industrial, and biothreat markets. Its systems enable molecular testing for organisms and genetic-based diseases by automation. Its SmartCycler system integrates DNA amplification and detection to allow rapid analysis of a sample; and GeneXpert system integrates sample preparation in addition to DNA amplification and detection. GeneXpert is designed for reference laboratories, hospital central laboratories, and satellite testing locations, such as ER and ICU units within hospitals, and doctorsÂ’ offices. In the clinical molecular diagnostic market, Cepheid markets tests for both the GeneXpert and the SmartCycler platforms in the areas of hospital acquired infections, critical infectious disease, immuno-compromised transplantation, womenÂ’s health, and oncology. These tests include Food and Drug Administration cleared products, such as in-vitro medical devices, CE Marked, analyte specific reagents, and research use only tests. In the industrial market, the company sells its SmartCycler along with general use polymerase chain reaction reagents and reaction tubes. Cepheid has tests available for anthrax, pestis, and tullarensis in the biothreat market. The company sells its products through direct sales and distribution channels worldwide. It has strategic relationship with bioMerieux, Inc. for bioMerieux to develop DNA testing products using nucleic acid sequence-based amplification technology. The company was founded in 1996 and is headquartered in Sunnyvale, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Thomas Gutshall , 70
Co-Founder and Chairman |
N/A
| N/A | Mr. John L. Bishop , 64
Chief Exec. Officer, Director and Member of Equity Incentive Committee |
$
488.00K |
$
11.61M | Mr. Andrew D. Miller , 48
Chief Financial Officer and Sr. VP |
$
365.00K | N/A | Mr. Humberto V. Reyes , 63
Chief Operating Officer and Exec. VP |
$
334.00K |
$
523.00K | Dr. David H. Persing Ph.D.,
Chief Technology Officer, Chief Medical Officer, Exec. VP, Director and Member of Equity Incentive Committee |
$
383.00K |
$
148.00K |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.48% Nasdaq 
Profile
